Coproporphyrin-1

CP-1 (Coproporphyrin-1) is a non-specific term that refers to several distinct entities in biomedical research, most notably an endogenous biomarker and a research control peptide. In clinical pharmacology, CP-1 is a porphyrin metabolite used as an **endogenous probe drug** to evaluate the activity of hepatic uptake transporters **OATP1B1** and **OATP1B3**. It is frequently utilized in Phase 1 clinical trials to assess **drug-drug interaction (DDI)** risks, as inhibition of these transporters by a candidate drug leads to elevated plasma CP-1 levels. In the specific context of Alzheimer's disease research (e.g., PMID 33756153), **CP-1** refers to a **control peptide** used as a negative control in the development of **GILZ analogs (GA)**. These analogs are designed to sequester activated **NF-kB p65** to suppress neuroinflammation, while CP-1 is a scrambled or mutated version intended to be inactive. Additionally, CP-1 can refer to **Poly(C)-binding protein 1 (PCBP1)**, an RNA-binding protein that regulates the translation of the **amyloid precursor protein (APP)** mRNA, making it a target of interest in Alzheimer's metallobiology.

Other names

Coproporphyrin IControl Peptide 1Poly(C)-binding protein 1PCBP1PCBP-1PCBP 1